IL147992A0 - Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof - Google Patents

Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Info

Publication number
IL147992A0
IL147992A0 IL14799201A IL14799201A IL147992A0 IL 147992 A0 IL147992 A0 IL 147992A0 IL 14799201 A IL14799201 A IL 14799201A IL 14799201 A IL14799201 A IL 14799201A IL 147992 A0 IL147992 A0 IL 147992A0
Authority
IL
Israel
Prior art keywords
specificity
necrosis factor
tumor necrosis
antibody molecules
human tumor
Prior art date
Application number
IL14799201A
Other languages
English (en)
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL147992(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of IL147992A0 publication Critical patent/IL147992A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
IL14799201A 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof IL147992A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (1)

Publication Number Publication Date
IL147992A0 true IL147992A0 (en) 2002-09-12

Family

ID=9893121

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14799201A IL147992A0 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
IL147992A IL147992A (en) 2000-06-06 2002-02-04 Molecules of antibodies specific for human TNF, compounds and compositions containing them, a DNA sequence encoding a heavy and light chain of said antibody and processes for the production of said antibody
IL195085A IL195085A0 (en) 2000-06-06 2008-11-03 Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL147992A IL147992A (en) 2000-06-06 2002-02-04 Molecules of antibodies specific for human TNF, compounds and compositions containing them, a DNA sequence encoding a heavy and light chain of said antibody and processes for the production of said antibody
IL195085A IL195085A0 (en) 2000-06-06 2008-11-03 Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody

Country Status (42)

Country Link
US (4) US7012135B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (4) EP1287140B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP4064812B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20020047097A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1289671C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2092A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR033978A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE451460T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU783756B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2010C019I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG66072B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BRPI0106682B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2707766C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (6) CY1109889T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ300737B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE60140738D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (4) DK1287140T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP024210A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (5) ES2707714T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR10C0015I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB0013810D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HU230561B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL147992A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (2) IS2808B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2308975T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91674I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA01013440A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY136603A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300982I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (4) NO334808B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ516596A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA12282A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20020292A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL218516B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (4) PT3059314T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2303604C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI2308975T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK288343B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR201900227T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI353358B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2001094585A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200200097B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
DK1495056T3 (da) * 2002-03-20 2011-05-02 Ucb Pharma Sa Fremgangsmåde til analyse af antistofdisulfidisomere
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
ES2370710T3 (es) * 2002-05-28 2011-12-22 Ucb Pharma, S.A. ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870).
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
DK1944322T3 (da) * 2002-07-19 2015-06-22 Abbvie Biotechnology Ltd Behandling af TNFalfa-relaterede sygdomme
WO2004019860A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1558640B1 (en) 2002-10-29 2011-04-13 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7575893B2 (en) * 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1597299A2 (en) * 2003-02-19 2005-11-23 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
EP1639011B1 (en) * 2003-06-30 2008-11-12 Domantis Limited Pegylated single domain antibodies (dAb)
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
EP1656452B1 (en) * 2003-08-13 2007-02-14 Sandoz AG Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
WO2005017174A2 (en) * 2003-08-13 2005-02-24 Sandoz Ag Process for the purification of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US8022040B2 (en) * 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
JP4642862B2 (ja) * 2004-12-29 2011-03-02 ユーハン・コーポレイション ヒト腫瘍壊死因子−アルファに特異的なヒト化抗体
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
RU2425054C2 (ru) * 2005-06-01 2011-07-27 Микромет Аг Антитела против il2
EP3260465A1 (en) 2005-06-07 2017-12-27 ESBATech, an Alcon Biomedical Research Unit LLC Stable and soluble antibodies inhibiting tnf-alpha
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
JP2009533347A (ja) * 2006-04-07 2009-09-17 ネクター セラピューティックス エイエル，コーポレイション 抗ＴＮＦα抗体の複合体
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080003230A1 (en) 2006-07-03 2008-01-03 Adair Charles D Composition for modulating the expression of cell adhesion molecules
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP5452236B2 (ja) * 2007-03-02 2014-03-26 ファーナム・カンパニーズ・インコーポレーテッド ロウ様物質を用いた徐放性組成物
EP2166844A4 (en) * 2007-06-07 2013-09-04 Evonik Corp DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
WO2009026274A1 (en) * 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
JP2011510667A (ja) * 2008-02-05 2011-04-07 デレネックス セラピューティクス アーゲー 軟骨変性に対する抗原結合性ポリペプチド
US8163885B2 (en) * 2008-05-07 2012-04-24 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
SI3722310T1 (sl) 2008-06-25 2025-01-31 Novartis Ag Stabilna in topna protitelesa, ki zavirajo vegf
CA2728004C (en) 2008-06-25 2022-05-24 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
KR20190133077A (ko) 2008-06-25 2019-11-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
SI2307458T1 (en) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
CA2749966A1 (en) * 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
WO2011036454A1 (en) 2009-09-24 2011-03-31 Ucb Pharma S.A. Bacterial host strain
EA201792376A3 (ru) 2009-10-23 2018-08-31 Милленниум Фармасьютикалз, Инк. Молекулы анти-gcc антитела и соответствующие композиции и способы
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
AU2011223547B2 (en) 2010-03-04 2016-05-05 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD52
CA2795734A1 (en) 2010-04-07 2011-10-13 Abbvie Inc. Tnf-.alpha. binding proteins
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
HUE039577T2 (hu) 2011-06-01 2019-01-28 Intrexon Actobiotics Nv Policisztronos expressziós rendszer baktériumokhoz
EP2731973B1 (en) 2011-07-13 2017-11-15 UCB Biopharma SPRL Bacterial host strain expressing recombinant dsbc
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
US9458467B2 (en) 2011-09-23 2016-10-04 Intrexon Actobiotics Nv Modified gram positive bacteria and uses thereof
WO2013041673A1 (en) 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
KR102193080B1 (ko) 2012-08-13 2020-12-18 제넨테크, 인크. 항-jagged 항체 및 사용 방법
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
LT3237433T (lt) 2014-12-22 2025-11-10 Baltymo gamybos būdas
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3919065B9 (en) 2016-01-14 2024-01-24 Intrexon Actobiotics NV Compositions and methods for the treatment of type 1 diabetes
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
CA3025377A1 (en) * 2016-06-02 2017-12-07 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
EP4591879A3 (en) 2019-01-31 2025-10-22 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202302626A (zh) 2021-02-15 2023-01-16 日商武田藥品工業股份有限公司 用於調節ｔｇｆ－ｂ信息傳導之細胞療法組成物及方法
US20250002527A1 (en) 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
AU2022349814A1 (en) 2021-09-24 2024-05-02 Xbrane Biopharma Ab Dna constructs and host cells for expressing recombinant protein
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CA2163032C (en) * 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1015480A2 (en) * 1997-08-18 2000-07-05 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
AU2903899A (en) 1998-03-12 1999-09-27 Shearwater Polymers Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
JP2009171966A (ja) 2009-08-06
HU230669B1 (hu) 2017-07-28
EP3059314B1 (en) 2018-10-24
PE20020292A1 (es) 2002-05-08
DK1287140T3 (da) 2010-04-19
PL212738B1 (pl) 2012-11-30
EP1287140A1 (en) 2003-03-05
IS6217A (is) 2002-01-03
BG66072B1 (bg) 2011-01-31
LU91674I2 (fr) 2010-05-31
HU230553B1 (hu) 2016-11-28
NO339282B1 (no) 2016-11-21
AR033978A1 (es) 2004-01-21
SI2308975T1 (sl) 2016-11-30
BG106278A (bg) 2002-12-29
NO20020554D0 (no) 2002-02-04
CZ300737B6 (cs) 2009-07-29
CY2019018I1 (el) 2020-05-29
ZA200200097B (en) 2003-01-06
MXPA01013440A (es) 2003-09-04
JP4064812B2 (ja) 2008-03-19
NO334808B1 (no) 2014-06-02
IS2808B (is) 2012-09-15
CY1121173T1 (el) 2020-05-29
NO2014026I2 (no) 2018-02-14
NO2014026I1 (no) 2014-10-23
ES2337763T3 (es) 2010-04-29
NO20160694A1 (no) 2002-04-08
NO20131316L (no) 2002-04-08
BR0106682A (pt) 2002-05-14
CA2707766A1 (en) 2001-12-13
CY2010011I1 (el) 2012-01-25
CN1289671C (zh) 2006-12-13
JP2007105043A (ja) 2007-04-26
PT1287140E (pt) 2010-03-08
NO341218B1 (no) 2017-09-11
BE2010C019I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2020-08-20
HK1051385A1 (en) 2003-08-01
IL195085A0 (en) 2009-08-03
TWI353358B (en) 2011-12-01
SK3152002A3 (en) 2002-07-02
US7402662B2 (en) 2008-07-22
PT3059314T (pt) 2019-02-01
ES2600080T3 (es) 2017-02-07
US7977464B2 (en) 2011-07-12
ATE451460T1 (de) 2009-12-15
CY2010011I2 (el) 2012-01-25
ECSP024210A (es) 2002-05-23
PT2308975T (pt) 2016-11-14
AU783756B2 (en) 2005-12-01
LT2308975T (lt) 2016-11-10
CN1383450A (zh) 2002-12-04
GB0128386D0 (en) 2002-01-16
CA2380298C (en) 2010-09-28
GB2366800A (en) 2002-03-20
HUP1600483A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-10-28
US7012135B2 (en) 2006-03-14
RU2303604C2 (ru) 2007-07-27
TWI316088B (en) 2009-10-21
NL300982I9 (nl) 2019-05-06
EP2308975A1 (en) 2011-04-13
HK1148776A1 (en) 2011-09-16
DE122010000027I1 (de) 2010-08-12
ES2230975A1 (es) 2005-05-01
GB0013810D0 (en) 2000-07-26
NL300982I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-05-01
PL218516B1 (pl) 2014-12-31
CA2707766C (en) 2013-05-21
EP2230308A1 (en) 2010-09-22
NO20020554L (no) 2002-04-08
FR10C0015I2 (fr) 2011-12-30
US20030026805A1 (en) 2003-02-06
CA2380298A1 (en) 2001-12-13
JP2003535591A (ja) 2003-12-02
ES2230975B2 (es) 2007-04-16
JP4476989B2 (ja) 2010-06-09
DK2308975T3 (da) 2016-10-31
KR20020047097A (ko) 2002-06-21
CZ2002837A3 (cs) 2002-05-15
FR10C0015I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-04-16
SI1287140T1 (sl) 2010-04-30
US20080269465A1 (en) 2008-10-30
DE10192353T1 (de) 2003-05-22
SK288343B6 (sk) 2016-04-01
DE60140738D1 (de) 2010-01-21
PL353960A1 (en) 2003-12-15
AP2092A (en) 2010-02-28
EP3059314A1 (en) 2016-08-24
AP2002002690A0 (en) 2002-12-31
ES2707714T3 (es) 2019-04-04
LU91674I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-03
ES2403217T3 (es) 2013-05-16
TR201900227T4 (tr) 2019-02-21
US7186820B2 (en) 2007-03-06
IS3016B (is) 2019-10-15
EP1287140B1 (en) 2009-12-09
HUP0202346A3 (en) 2004-11-29
CY1114143T1 (el) 2016-07-27
WO2001094585A1 (en) 2001-12-13
DK3059314T3 (en) 2019-02-18
NZ516596A (en) 2004-07-30
HUS1700013I1 (hu) 2017-08-28
HUP1600016A2 (en) 2002-10-28
PL399351A1 (pl) 2012-12-17
AU6051101A (en) 2001-12-17
HU230561B1 (hu) 2016-12-28
CY1118220T1 (el) 2017-06-28
IL147992A (en) 2009-06-15
US20060233800A1 (en) 2006-10-19
SI2230308T1 (sl) 2013-06-28
BRPI0106682B8 (pt) 2021-05-25
CY2019018I2 (el) 2020-05-29
OA12282A (en) 2006-05-11
BRPI0106682B1 (pt) 2020-10-13
DK2230308T3 (da) 2013-05-06
PT2230308E (pt) 2013-05-03
TW200817430A (en) 2008-04-16
MY136603A (en) 2008-10-31
CY1109889T1 (el) 2012-01-25
JP5185143B2 (ja) 2013-04-17
HUP0202346A2 (en) 2002-10-28
EP2230308B1 (en) 2013-01-23
GB2366800B (en) 2005-01-19
US20020151682A1 (en) 2002-10-17
EP2308975B1 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
HUS1700013I1 (hu) Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk
EP2940044B8 (en) Anti-tnf alpha antibodies for use in therapy
HUP0400284A3 (en) Recombinant tumor specific antibody and use thereof
IL202332A0 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU2868601A (en) Biaryl compounds, their preparation and their use in therapy
GB0115780D0 (en) Therapeutic molecules and uses thereof
HK1052013A (en) Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy
AUPR073100A0 (en) Novel therapeutic molecules and uses therefor - vii
AUPQ884400A0 (en) Novel therapeutic molecules and uses therefor - II
AUPR073000A0 (en) Novel therapeutic molecules and uses therefor - iv
AUPQ884200A0 (en) Novel therapeutic molecules and uses therefor - I
AUPR073300A0 (en) Novel therapeutic molecules and uses therefor - V
AUPR073200A0 (en) Novel therapeutic molecules and uses therefor - VI
AUPQ670400A0 (en) Novel therapeutic molecules and uses therefor
AU2001228686A1 (en) Biaryl compounds, their preparation and their use in therapy
GB0002559D0 (en) Virulencegene and protein and their use
AUPQ549800A0 (en) Therapeutic and diagnostic molecules